A Big Win for Diabetic Kidney Disease: CREDENCE

Cherney David Z. I.; David Z.I. Chemey; Odutayo AyodeleAyodele OdutayoVerma SubodhSubodh Verma

首页> 外文期刊>Cell metabolism >A Big Win for Diabetic Kidney Disease: CREDENCE

【24h】

A Big Win for Diabetic Kidney Disease: CREDENCE

机译：A Big Win for Diabetic Kidney Disease: CREDENCE

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

Sodium glucose co-transporter 2 (SGLT2) inhibitors are glucose-lowering agents used for the treatment of type 2 diabetes (T2D). By blocking SGLT2 at the renal proximal tubule, these agents induce glu-cosuria, which in turn reduces hypergly-cemia and body weight. SGLT2 inhibitors promote natriuresis, which has been associated with blood pressure lowering via contraction of plasma volume (Heer-spink et al., 2016). Natriuresis also contributes to reductions in intraglomerular hypertension, hyperfiltration, and albu-minuria through activation of tubuloglo-merular feedback (Verma and McMurray, 2018; Verma et al., 2017) (Figure 1).

著录项

来源
《Cell metabolism》 |2019年第5期|1024-1027|共4页
作者
Cherney David Z. I.; David Z.I. Chemey; Odutayo AyodeleAyodele OdutayoVerma SubodhSubodh Verma;
展开▼
作者单位

Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Appl Hlth Res Ctr, Toronto, ON, Canada;

Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON, Canada;

Toronto Gen Hosp, Div Nephrol, Toronto, ON, CanadaDivision of Nephrology, Toronto General Hospital, Toronto, ON, Canada;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类内分泌腺疾病及代谢病;
关键词

A Big Win for Diabetic Kidney Disease: CREDENCE

摘要

著录项

相关主题

期刊订阅